Lynn Baglyos

Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial

W. Blattner, S. Self, D. Montefiori, 2007, Journal of acquired immune deficiency syndromes.

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.

T. Flynn, R. Bosch, E. Adams, 2009, Vaccine.

A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime With Oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 (CM235/SF2) Boost

Jerome H. Kim, D. Birx, R. Paris, 2007, Journal of acquired immune deficiency syndromes.

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

S. Gurunathan, J. Tartaglia, S. Plotkin, 2004, Expert review of vaccines.

Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1–Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa

P. Kaleebu, N. Jones, M. Fowler, 2014, Journal of acquired immune deficiency syndromes.

Use of predictive markers of HIV disease progression in vaccine trials.

S. Gurunathan, J. Tartaglia, L. Corey, 2009, Vaccine.

Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1–Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa

P. Kaleebu, N. Jones, M. Fowler, 2014, Journal of acquired immune deficiency syndromes.